A platform company with revolutionary technology enabling us to find and quantify thousands of small proteins that no one else can see, then rapidly determine their medically-relevant biological activity.
We partner with large and small companies to screen for biologics in disease areas of interest from human and non-humans species. These activities are complemented by our own internal drug development programs.
Our technology can typically detect an additional 5-10% of any species' proteome, which is currently missed by other technologies, allowing us to accelerate drug research and development programs.
Our proprietary software and peptide discovery pipeline sees thousands of proteins that no others can.
We see 5-10% more of the proteome than anyone else and can rapidly screen them for biological functions.
Peptides we discover are taken through development as biologics for rare and common diseases.